ESTEVE PHARMACEUTICALS

Live / Registered — Registered (as of 13 Jan 2026)

What this means for you

Registered since 13 Jan 2026. The owner can stop confusingly similar uses in the classes it covers.

Record

Serial number
99044353
Registration number
8099251
Mark type
Stylized text
Filed
17 Feb 2025
Published for opposition
25 Nov 2025
Registered
13 Jan 2026
Attorney of record
G Patrick SAGE II

Goods and services

  • Class 005 — Pharmaceuticals: Pharmaceutical preparations for the treatment of metabolic disorders, namely, for treating diabetes, hypoglycaemia, gout, osteoarthritis, muscular dystrophy, anemia, bulimia nervosa, anorexia, obesity and hypothyroidism; Pharmaceutical preparations for the treatment of the endocrine system, namely, for treating growth and thyroid disorders; Pharmaceutical preparations for the treatment of the musculoskeletal system, namely, for treating connective tissue diseases, bone diseases, spinal diseases, back pain, fractures, sprains, and cartilage injuries; Pharmaceutical preparations for the treatment of genitourinary diseases, namely, for treating urological diseases, infertility, sexually transmitted diseases, and inflammatory pelvic diseases; Pharmaceutical preparations for the treatment of neurological diseases, namely, for use in treating Alzheimer's disease, Huntington's disease, cerebral palsy, brain injuries, spinal cord injuries, and seizure disorders; Pharmaceutical preparations for the treatment of hormonal disorders, namely, corticosteroids, hormone replacement therapy preparations, oral contraceptives, and thyroid hormone preparations; Pharmaceutical preparations for the treatment of psychiatric diseases, namely, for treating mood disorders, anxiety disorders, cognitive disorders, schizophrenia and bipolar disorders; Pharmaceutical preparations for the treatment of cardiovascular, cardiopulmonary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, gastrointestinal, and immune system related diseases and disorders; Pharmaceutical preparations for use in dermatology, namely, for use in treating dermatitis, eczema, psoriasis, skin pigmentation diseases, and dermatological sexually transmitted diseases

Owner

Prosecution history

  • 13 Jan 2026 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
  • 13 Jan 2026 — REGISTERED-PRINCIPAL REGISTER
  • 25 Nov 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
  • 25 Nov 2025 — PUBLISHED FOR OPPOSITION
  • 19 Nov 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
  • 27 Oct 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
  • 27 Oct 2025 — EXAMINER'S AMENDMENT ENTERED
  • 27 Oct 2025 — NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
  • 27 Oct 2025 — EXAMINERS AMENDMENT E-MAILED
  • 27 Oct 2025 — EXAMINERS AMENDMENT -WRITTEN
  • 24 Oct 2025 — TEAS/EMAIL CORRESPONDENCE ENTERED
  • 24 Oct 2025 — CORRESPONDENCE RECEIVED IN LAW OFFICE
  • 24 Oct 2025 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
  • 26 Jul 2025 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
  • 26 Jul 2025 — NON-FINAL ACTION E-MAILED

View this trademark record on Marksy